Does the media favor RNAC or PLRX?

In the previous week, Cartesian Therapeutics had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 2 mentions for Cartesian Therapeutics and 1 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.59 beat Cartesian Therapeutics' score of 0.00 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pliant Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ALXO or PLRX more profitable?

Pliant Therapeutics' return on equity of -52.17% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -90.30% -67.28% Pliant Therapeutics N/A -52.17% -40.46%

Does the media favor ALXO or PLRX?

In the previous week, ALX Oncology had 3 more articles in the media than Pliant Therapeutics. MarketBeat recorded 4 mentions for ALX Oncology and 1 mentions for Pliant Therapeutics. ALX Oncology's average media sentiment score of 1.26 beat Pliant Therapeutics' score of 0.59 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pliant Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PLRX or TRDA?

In the previous week, Entrada Therapeutics had 15 more articles in the media than Pliant Therapeutics. MarketBeat recorded 16 mentions for Entrada Therapeutics and 1 mentions for Pliant Therapeutics. Entrada Therapeutics' average media sentiment score of 0.67 beat Pliant Therapeutics' score of 0.59 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ACIU or PLRX?

In the previous week, AC Immune had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 2 mentions for AC Immune and 1 mentions for Pliant Therapeutics. AC Immune's average media sentiment score of 1.25 beat Pliant Therapeutics' score of 0.59 indicating that AC Immune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AC Immune 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pliant Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend YDES or PLRX?

Pliant Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 165.49%. Given Pliant Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pliant Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75

Which has preferable earnings and valuation, YDES or PLRX?

YD Bio has higher earnings, but lower revenue than Pliant Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio YD Bio N/A N/A N/A N/A N/A Pliant Therapeutics $1.58M 44.28 -$149.34M -$1.49 N/A

Is YDES or PLRX more profitable?

YD Bio's return on equity of 0.00% beat Pliant Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets YD Bio N/A N/A N/A Pliant Therapeutics N/A -52.17% -40.46%

Does the media prefer YDES or PLRX?

In the previous week, YD Bio had 5 more articles in the media than Pliant Therapeutics. MarketBeat recorded 6 mentions for YD Bio and 1 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.59 beat YD Bio's score of 0.32 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment YD Bio 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pliant Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pliant Therapeutics (PLRX) Competitors

$1.13 -0.03 (-2.59%)

As of 09/3/2026 04:00 PM Eastern

Compare

PLRX vs. RNAC, ALXO, TRDA, ACIU, and YDES

Should you buy Pliant Therapeutics stock or one of its competitors? Pliant Therapeutics's main competitors and comparable companies include Cartesian Therapeutics (RNAC), ALX Oncology (ALXO), Entrada Therapeutics (TRDA), AC Immune (ACIU), and YD Bio (YDES). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pliant Therapeutics compare to Cartesian Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Cartesian Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Pliant Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%
Pliant Therapeutics	N/A	-52.17%	-40.46%

Cartesian Therapeutics has higher revenue and earnings than Pliant Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	98.53	-$130.30M	-$5.94	N/A
Pliant Therapeutics	$1.58M	44.28	-$149.34M	-$1.49	N/A

In the previous week, Cartesian Therapeutics had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 2 mentions for Cartesian Therapeutics and 1 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.59 beat Cartesian Therapeutics' score of 0.00 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pliant Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cartesian Therapeutics currently has a consensus target price of $32.60, indicating a potential upside of 257.46%. Pliant Therapeutics has a consensus target price of $3.00, indicating a potential upside of 165.49%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 37.2% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Cartesian Therapeutics beats Pliant Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Pliant Therapeutics compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 12.4% of ALX Oncology shares are owned by company insiders. Comparatively, 8.7% of Pliant Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ALX Oncology has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

In the previous week, ALX Oncology had 3 more articles in the media than Pliant Therapeutics. MarketBeat recorded 4 mentions for ALX Oncology and 1 mentions for Pliant Therapeutics. ALX Oncology's average media sentiment score of 1.26 beat Pliant Therapeutics' score of 0.59 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pliant Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ALX Oncology currently has a consensus price target of $4.60, suggesting a potential upside of 126.60%. Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 165.49%. Given Pliant Therapeutics' higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Pliant Therapeutics' return on equity of -52.17% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-90.30%	-67.28%
Pliant Therapeutics	N/A	-52.17%	-40.46%

ALX Oncology has higher earnings, but lower revenue than Pliant Therapeutics. ALX Oncology is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A
Pliant Therapeutics	$1.58M	44.28	-$149.34M	-$1.49	N/A

Summary

ALX Oncology beats Pliant Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Pliant Therapeutics compare to Entrada Therapeutics?

Pliant Therapeutics (NASDAQ:PLRX) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Pliant Therapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

Pliant Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. Pliant Therapeutics' return on equity of -52.17% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-52.17%	-40.46%
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%

Entrada Therapeutics has higher revenue and earnings than Pliant Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	44.28	-$149.34M	-$1.49	N/A
Entrada Therapeutics	$25.42M	10.98	-$143.75M	-$3.96	N/A

Pliant Therapeutics presently has a consensus price target of $3.00, indicating a potential upside of 165.49%. Entrada Therapeutics has a consensus price target of $17.75, indicating a potential upside of 147.56%. Given Pliant Therapeutics' higher probable upside, equities research analysts clearly believe Pliant Therapeutics is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 8.7% of Pliant Therapeutics shares are owned by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Entrada Therapeutics had 15 more articles in the media than Pliant Therapeutics. MarketBeat recorded 16 mentions for Entrada Therapeutics and 1 mentions for Pliant Therapeutics. Entrada Therapeutics' average media sentiment score of 0.67 beat Pliant Therapeutics' score of 0.59 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pliant Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entrada Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Pliant Therapeutics beats Entrada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Pliant Therapeutics compare to AC Immune?

AC Immune (NASDAQ:ACIU) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

In the previous week, AC Immune had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 2 mentions for AC Immune and 1 mentions for Pliant Therapeutics. AC Immune's average media sentiment score of 1.25 beat Pliant Therapeutics' score of 0.59 indicating that AC Immune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pliant Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Comparatively, 8.7% of Pliant Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

AC Immune has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

AC Immune presently has a consensus target price of $7.50, indicating a potential upside of 155.97%. Pliant Therapeutics has a consensus target price of $3.00, indicating a potential upside of 165.49%. Given Pliant Therapeutics' higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Pliant Therapeutics has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Pliant Therapeutics' return on equity of -52.17% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-245.32%	-100.17%	-28.36%
Pliant Therapeutics	N/A	-52.17%	-40.46%

AC Immune has higher revenue and earnings than Pliant Therapeutics. AC Immune is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	69.18	-$85.03M	-$0.54	N/A
Pliant Therapeutics	$1.58M	44.28	-$149.34M	-$1.49	N/A

Summary

AC Immune beats Pliant Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Pliant Therapeutics compare to YD Bio?

YD Bio (NASDAQ:YDES) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, YD Bio had 5 more articles in the media than Pliant Therapeutics. MarketBeat recorded 6 mentions for YD Bio and 1 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.59 beat YD Bio's score of 0.32 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
YD Bio	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pliant Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

YD Bio has higher earnings, but lower revenue than Pliant Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
YD Bio	N/A	N/A	N/A	N/A	N/A
Pliant Therapeutics	$1.58M	44.28	-$149.34M	-$1.49	N/A

97.3% of Pliant Therapeutics shares are held by institutional investors. 8.7% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Pliant Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 165.49%. Given Pliant Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

YD Bio's return on equity of 0.00% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
YD Bio	N/A	N/A	N/A
Pliant Therapeutics	N/A	-52.17%	-40.46%

Summary

Pliant Therapeutics beats YD Bio on 7 of the 10 factors compared between the two stocks.

Get Pliant Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLRX vs. The Competition

Export

Metric	Pliant Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$71.83M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.76	12.66	273.28	25.38
Price / Sales	44.28	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	0.48	16.29	12.89	6.14
Net Income	-$149.34M	-$22.72M	$3.47B	$349.01M
7 Day Performance	1.80%	0.34%	0.61%	-0.27%
1 Month Performance	7.62%	8.52%	5.73%	0.68%
1 Year Performance	-30.67%	52.66%	25.37%	14.84%

Pliant Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLRX Pliant Therapeutics	2.3052 of 5 stars	$1.13 -2.6%	$3.00 +165.5%	-33.9%	$71.83M	$1.58M	N/A	90
RNAC Cartesian Therapeutics	1.6931 of 5 stars	$9.18 -1.1%	$32.60 +255.2%	-11.0%	$273.88M	$2.80M	N/A	64
ALXO ALX Oncology	2.6063 of 5 stars	$1.98 +2.3%	$4.60 +132.9%	+99.0%	$273.10M	N/A	N/A	40	Positive News
TRDA Entrada Therapeutics	2.4624 of 5 stars	$7.02 -0.5%	$17.75 +153.0%	+34.8%	$272.93M	$25.42M	N/A	110	News Coverage Analyst Upgrade Insider Trade
ACIU AC Immune	2.6972 of 5 stars	$2.66 +0.6%	$7.50 +182.5%	+29.6%	$270.20M	$4.31M	N/A	140	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLRX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pliant Therapeutics (PLRX) Competitors

PLRX vs. RNAC, ALXO, TRDA, ACIU, and YDES

How does Pliant Therapeutics compare to Cartesian Therapeutics?

Summary

How does Pliant Therapeutics compare to ALX Oncology?

Summary

How does Pliant Therapeutics compare to Entrada Therapeutics?

Summary

How does Pliant Therapeutics compare to AC Immune?

Summary

How does Pliant Therapeutics compare to YD Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pliant Therapeutics (PLRX) Competitors

PLRX vs. RNAC, ALXO, TRDA, ACIU, and YDES

How does Pliant Therapeutics compare to Cartesian Therapeutics?

Which has more volatility and risk, RNAC or PLRX?

Is RNAC or PLRX more profitable?

Which has stronger valuation & earnings, RNAC or PLRX?

Does the media favor RNAC or PLRX?

Do analysts recommend RNAC or PLRX?

Do institutionals & insiders believe in RNAC or PLRX?

Summary

How does Pliant Therapeutics compare to ALX Oncology?

Do insiders and institutionals hold more shares of ALXO or PLRX?

Which has more volatility and risk, ALXO or PLRX?

Does the media favor ALXO or PLRX?

Do analysts rate ALXO or PLRX?

Is ALXO or PLRX more profitable?

Which has better valuation and earnings, ALXO or PLRX?

Summary

How does Pliant Therapeutics compare to Entrada Therapeutics?

Which has more volatility and risk, PLRX or TRDA?

Is PLRX or TRDA more profitable?

Which has preferable valuation & earnings, PLRX or TRDA?

Do analysts prefer PLRX or TRDA?

Do insiders & institutionals have more ownership in PLRX or TRDA?

Does the media refer more to PLRX or TRDA?

Summary

How does Pliant Therapeutics compare to AC Immune?

Does the media prefer ACIU or PLRX?

Do insiders and institutionals believe in ACIU or PLRX?

Which has more risk & volatility, ACIU or PLRX?

Do analysts prefer ACIU or PLRX?

Is ACIU or PLRX more profitable?

Which has preferable valuation & earnings, ACIU or PLRX?

Summary

How does Pliant Therapeutics compare to YD Bio?

Does the media prefer YDES or PLRX?

Which has preferable earnings and valuation, YDES or PLRX?

Do institutionals and insiders have more ownership in YDES or PLRX?

Do analysts recommend YDES or PLRX?

Is YDES or PLRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools